NotebookLM is your next productivity powerhouse ...

New Opentrons AI capability lets scientists simulate and visually inspect automated laboratory experiments before robots ...

Independent music production has never been more creatively viable — or more logistically demanding. The independent producer ...

Docs rot faster than fruit. You refactor a function signature on Monday. The docs still show the old signature on Friday. By next month, half your documentation is lying to your users. Formatting is ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year. 2025 was a slow year for IPOs, with ...

Katelyn is a writer with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...